Audit: QRS - Microdosing Ketamine for Health & Longevity
Audit conducted on 05/08/2026 02:41 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 81 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol, time-to-effect, benefit/risk tiers, gates, monitoring targets and qualitative markers all trace to ER lines 383, 411–421, 466, 492–510. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | At-A-Glance carries the ER Conclusion’s hedges (“unsettled”, “thinner ground”, “never been mapped”). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications retain absolute framing; interactions remain interactions. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gates drawn only from Key Interactions & Contraindications; no modifying-factor content leaks into any card. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, citations, expert names, NCT IDs or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, evidence-status framing matching the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and tiers presented without alarmism or exhortation. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Statements are descriptive; no imperatives. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No prescriptive verbs in any populated span. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Protocol cells state observed regimens, not recommendations. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Retained technical terms (Child-Pugh, NYHA class) are decision-gate qualifiers required by 8.5. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are noun-phrase length; no elaborations. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text scan for “you”/”your”. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Monitoring panel with functional (not conventional) ranges is aimed at this audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Per-dose blood-pressure checks and quarterly panels assume this willingness. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content depth and biomarker granularity exceed general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance foregrounds the unmapped ceiling for repeated home use, the audience-specific issue. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “lozenge”, “rapid-dissolve tablet”, “dissociation”, “sublingual” used in the document’s own voice; plain-language wording is confined to At-A-Glance as 7.4 requires. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All headings verified verbatim at lines 444, 494, 545, 576, 598, 632, 666, 670–672, 797. |
| 3.2 | All “<span data-qrs-var=”NAME”>…</span>” from the [qrs_template] are present in the the QRS. | 🟢 | 64 distinct spans present, no duplicates, complete sequential sets for action/time/benefits/risks/marker/qualitative. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Non-variable template elements (website="evidence_review", website="audit", website="full_review") untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section mapped into the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels and all six Qualitative Assessment labels match ER bold labels verbatim (ER lines 411, 413, 421, 505–510). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels derive from ER benefit headings; no invented labels. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in the QRS; ER tier emoji are dropped in favour of CSS palettes and bold tier labels. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to the minimum permitted by 8.5, 12.3, 13.3, 14.2 and 15.2; no section carries surplus prose. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–13, immediately after the doctype. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- line 3, closing --- line 12. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no duplicate rendering elsewhere. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:05" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: microdosing_ketamine_2026-0805-0004_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0805-0215. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the actual file name. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Verified — no trailing whitespace on any frontmatter line. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 21: “Microdosing Ketamine for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 416: “Microdosing Ketamine for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0805-0215 → “08/05/2026” at line 420. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 424: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only title and the template subline; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER lines 538–540: efficacy status, dose-response caveat, non-mood claims, acute effects, unmapped ceiling. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct sentence in ER lines 538–540. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “detachment” replaces “dissociation”, “controlled human research” replaces trial nomenclature. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric effect measures present. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All twelve items map to ER line 383 (“Populations who should avoid this intervention”). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | ER lists 12 populations; QRS lists all 12. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 579–593, twelve <li> elements. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Explanatory glosses (arteriovenous malformation definition, Child-Pugh explanation, interstitial cystitis definition) are stripped; the only dash is the range “III–IV”. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(above 160/100 mmHg)”, “within 90 days”, “Class III–IV”, “Child-Pugh Class B or C”, “(dissociatives, alcohol)”, “at least two hours” all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER contraindication bullet uses no ranking notation inside parentheses. |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | [stop_items] are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items map to ER lines 363–381. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Ten ER interaction bullets → ten items; no overlap with the twelve contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 601–622, ten <li> elements. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER “— caution, …” clause and mitigation sentence is stripped; no dashes remain in the list. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every item retains a named-example parenthetical; longer ER lists are shortened rather than dropped. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER interaction bullets use no ranking notation inside parentheses. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | [caution_items] are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Maps to ER Therapeutic Protocol lines 411, 413, 421. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The two microdosing regimens plus dose timing — the aspects an implementer must fix first. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct aspects are present and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans populated with ER-derived dose, frequency, route and hold-time detail. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Depressive symptoms and sustained benefit from ER line 466; anxiety onset from ER lines 187–189. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | High-tier depressive-symptom benefit first, then two Medium-tier benefits. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct aspects are present and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated from ER lines 187–189 and 466. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information (line 466). |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All items are ER Expected Benefits sub-headings (lines 159–235). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at lines 547–569. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Headings only; no magnitude, mechanism or grading rationale carried across. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any benefit item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All items are ER Potential Risks & Side Effects sub-headings (lines 261–345). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated at lines 634–660. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Headings only; magnitudes and “⚠️ Conflicted” markers dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows mirror the ER biomarker table at lines 492–501. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER biomarkers present: blood pressure, resting heart rate, ALT/AST, GGT, creatinine/eGFR, urinalysis, hs-CRP, fasting glucose/HbA1c. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 787–791 condense ER line 490 across all four cadences. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Maps to ER qualitative markers at lines 505–510. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six present: mood level and stability, sleep quality and continuity, cognitive clarity, urinary symptoms, emotional range, relationship to the dose. |
Issues 05/08/2026 02:41
Pass rate 100.00%. No issues found.
Issues 05/08/2026 02:34
- 9.5 — Dose qualifier dropped from examples: In the Key Interactions gate, line 605 lists “caffeine” and line 613 lists “melatonin”, whereas the ER specifies “high-dose caffeine” (ER line 371) and “high-dose melatonin” (ER line 377), widening both cautions to the substance in general.
Fixes 05/08/2026 02:34
- 9.5 — Dose qualifier restored to examples: In the Key Interactions gate, “caffeine” was changed back to “high-dose caffeine” and “melatonin” to “high-dose melatonin”, matching the ER’s own qualifiers.
Issues 05/08/2026 02:25
- 4.5 — One-page A4 budget exceeded: With ~895 words of body text, 12 contraindication items, 10 interaction items, 8 biomarker rows and a four-line cadence, the sheet overruns a single A4 page at the template’s 9.5pt/1.42 metrics; the gate and monitoring sections were not condensed to their per-section budget.
Fixes 05/08/2026 02:25
- 4.5 — Decision gates condensed: Trimmed the Contraindications and Key Interactions items to their load-bearing facts (e.g. “Uncontrolled hypertension (resting blood pressure above 160/100 mmHg)” → “Uncontrolled hypertension (above 160/100 mmHg)”), shortening the example drug lists per item 9.5 without dropping any of the 12 stop items or 10 caution items.
- 4.5 — Monitoring cells and cadence shortened: Condensed the cadence sentence and the GGT, urinalysis and glucose rationales (e.g. “Most sensitive early marker of biliary irritation, the pattern seen in ketamine cholangiopathy” → “Most sensitive early marker of biliary irritation”), removing three wrapped table lines while keeping all 8 biomarkers.
- 4.5 — Protocol and qualitative text tightened: Trimmed the three protocol sub-lines and three Qualitative Assessment items to single-line length, reducing total body text from ~895 to ~835 words.